GALEAS Bladder: A Non-Invasive Urine Test for Bladder Cancer

Blood in your urine?

A simple, non-invasive urine test that checks for signs of bladder cancer.

GALEAS Bladder analyses DNA in a urine sample to look for changes linked to bladder cancer, helping you and your clinician decide whether further investigation is needed. • Simple urine sample — completely non-invasive • Examines 23 genes associated with bladder cancer • Analysed by Nonacus, a UK genomic laboratory, as an ISO 15189:2022-accredited service •

Order GALEAS Bladder — £549

How it works

1. Order online.

2. Provide a urine sample at home.

3. Post to the lab in the prepaid packaging.

4. Get results in 10–14 days with guidance on next steps.

What it measures: targeted next-generation sequencing detects tumour-derived DNA changes across 23 bladder-cancer-associated genes in urine.

Order GALEAS Bladder — £549

Q: Is this a general cancer screen?

A: No — it’s for people who already have blood in their urine, or who need monitoring.

Q: Does it replace cystoscopy?

A: No — it helps decide whether cystoscopy or other investigation is needed.

Q: How much does it cost and how fast are results?

A: £549, results in 10–14 days.

Services We Provide

Nonacus Clinical Services (UK Partner)

Specialism:

Genomics & Hereditary Cancer

Description:

Birmingham-based specialist genomics laboratory operating as Informed Genomics Limited, trading as Nonacus Clinical Services. Nonacus provides MeCheck’s hereditary cancer panel testing, bladder cancer (GALEAS®) liquid biopsy analysis, and molecular genomics services.

Accreditations:

UKAS ISO 15189:2022
Schedule No. 22262
ISO 27001 Data Security
GDPR Compliant
ACMG / ACGS Variant Guidelines

Footnote:

Accreditation issued by the United Kingdom Accreditation Service (UKAS) — the sole national accreditation body recognised by the British Government. Accreditation assessed annually.

Biovis Diagnostik MVZ GmbH (Germany Partner)

Specialism:

Bowel Cancer Screening

Description:

Specialist medical laboratory based in Limburg-Eschhofen, Germany, with over a decade of expertise in stool diagnostics, microbiome analysis, and cancer screening. Biovis provides MeCheck’s bowel cancer (ColoAlert®) testing services.

Accreditations:

DAkkS ISO 15189:2024
DIN EN ISO 15189
Stool Diagnostics Specialist
EQA Scheme Participant

Footnote:

Accreditation issued by Deutsche Akkreditierungsstelle (DAkkS) — Germany’s national accreditation body, operating under EU Regulation 765/2008. Equivalent in standing to UKAS accreditation in the UK.

Bloodo / LifeLab1 (Lithuania Partner)

Specialism:

NAD, NMN & Cellular Wellness

Description:

Bloodo is a Vilnius-based clinical diagnostics company operating LifeLab1, a fully licensed clinical laboratory specialising in dried blood spot (DBS) testing, liquid chromatography/mass spectrometry (LC/MS), and advanced metabolic biomarker analysis. Bloodo provides MeCheck’s NAD and NMN cellular wellness testing services.

LifeLab1 maintains quality standards aligned with ISO 15189 and participates in international external quality assurance (EQA) programmes to ensure consistent, reliable results. The laboratory team comprises experienced medical biologists, quality specialists, PhD candidates, and doctors of pharmacy. Collaborative research is conducted with Vilnius University (Lithuania) and Malmö University (Sweden).

Licences and standards:

ISO 15189 Aligned
CE Marked · IVDR 2017/746
EN ISO 13485 Manufacturing
LHP-2819 Licensed
NR-4864 State Accredited
NM-334 Licensed

Footnote:

Regulated by Lithuanian state health authorities and the Lithuanian National Accreditation Bureau (LA) — a full ILAC MRA signatory and member of the European Accreditation (EA) network.

26-27_Working together to untangle IVDR_022023_img1.png

Additional standards

CE / IVDR — Clinically Validated Test Kits:

All test kits supplied by MeCheck carry CE marking under the EU In Vitro Diagnostic Regulation (IVDR), confirming they meet rigorous safety, performance, and clinical validity requirements before reaching consumers.

Clinical Review — Medically Reviewed Results:

All products are assessed for clinical appropriateness by Dr Tang before listing. Results are benchmarked against current clinical reference ranges and provided with clear, actionable guidance.

Who it’s for

GALEAS Bladder is designed for adults who have noticed blood in their urine (visible or found on a test) and want to assess their risk of bladder cancer, and to support monitoring after previous bladder-cancer treatment. This is a testing service, not a diagnosis, and does not replace advice from your doctor. Visible blood in your urine should always be checked by a doctor. Use this test alongside — not instead of — medical assessment.